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ABSTRACT 
 
Background: The natural history of ductal carcinoma in situ (DCIS) remains uncertain. The 
risk factors for the development of invasive cancer in unresected DCIS are unclear. 
 
Methods: Women diagnosed with DCIS on needle biopsy after 1997 who did not undergo 
surgical resection for ≥1 year after diagnosis were identified by breast centres and the 
cancer registry and outcomes were reviewed. 
 
Results: Eighty-nine women with DCIS diagnosed 1998-2010 were identified. The median 
age at diagnosis was 75 (range 44-94) years with median follow-up (diagnosis to death, 
invasive disease or last review) of 59 (12-180) months. Twenty-nine women (33%) 
developed invasive breast cancer after a median interval of 45 (12-144) months. 14/29 
(48%) with high grade, 10/31 (32%) with intermediate grade and 3/17 (18%) with low grade 
DCIS developed invasive cancer after median intervals of 38, 60 and 51 months. The 
cumulative incidence of invasion was significantly higher in high grade DCIS than other 
grades (p=0.0016, log-rank test). Invasion was more frequent in lesions with calcification as 
the predominant feature (23/50 v. 5/25; p=0.042) and in younger women (p=0.0002). 
Endocrine therapy was associated with a lower rate of invasive breast cancer (p=0.048).  
 
Conclusions: High cytonuclear grade, mammographic microcalcification, young age and lack 
of endocrine therapy were risk factors for DCIS progression to invasive cancer. Surgical 
excision of high grade DCIS remains the treatment of choice. Given the uncertain long-term 
natural history of non-high grade DCIS, the option of active surveillance of women with this 
condition should be offered within a clinical trial. 
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1. INTRODUCTION 
 
Ductal carcinoma in situ (DCIS) is diagnosed predominantly through mammographic 
screening programmes and now comprises 20% or more of new breast cancers. [1] Concern 
has been expressed regarding possible overtreatment, [2] given the excellent long term 
survival of women with DCIS. [3,4] Some have suggested that “nothing is better than 
something” [5] and proposed long-term surveillance for estrogen receptor (ER) positive 
DCIS. [6,7]  Randomised trials comparing the outcomes of active surveillance (AS) with 
conventional surgery and adjuvant treatment have opened in the UK (the LORIS trial), [8] 
the US (the COMET trial) [9] and Europe (the LORD trial). [10] Endocrine therapy in the AS 
arms is optional in COMET, optional but not encouraged in LORIS and not allowed in LORD. 
 
While there is an historic literature describing the natural history of DCIS in small, 
predominantly pre-screening series of symptomatic disease, [11] there is also a growing 
understanding that DCIS is a heterogeneous condition. It has been reported as a common 
incidental finding at autopsy with a median 8.9% prevalence in a review of seven studies of 
women who died of unrelated causes. [12] These series, conducted over 30 years ago, used 
variable diagnostic criteria, compounded by the difficulty of diagnosing DCIS in tissue that is 
likely to have been poorly preserved. The current prevalence of undiagnosed DCIS therefore 
remains uncertain. 
 
Whatever the true prevalence, surgery, radiotherapy and endocrine therapy remain the 
mainstays of guideline-concordant care. However, some 2.0-2.3% of patients diagnosed 
with DCIS in the USA choose AS for management of their disease. [4,13] Without treatment, 
it has been estimated that only 20-30% of DCIS will progress to invasive cancer. [11,14] 
Furthermore, it is not known whether long-term disease outcome is adversely impacted by 
awaiting progression to invasive disease.   
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Given this background, we sought to identify women in the recent breast screening era who 
had not received surgical resection for histologically diagnosed DCIS and to consider risk 
factors and long-term outcomes for such women as a comparator for active surveillance 
trials. 
 
 
2. MATERIAL AND METHODS 
 
2.1. The West Midlands Cancer Intelligence Unit (WMCIU, now incorporated into the 
National Cancer Registration and Analysis Service, part of Public Health England) and the 
Scottish Cancer Registry identified 2505 possible eligible patients from cancer registrations 
of women diagnosed in England and Scotland between 1 January 1996 and 31 December 
2009. These women had a needle biopsy diagnosis of DCIS but no record of subsequent 
surgery. Details were sent to Lead Clinicians in each hospital following completion of a 
confidentiality agreement. In addition, National Health Service (NHS) Breast Units and NHS 
Breast Screening Programme (NHSBSP) centres in the United Kingdom were invited to 
submit details of known patients with DCIS diagnosed from 1 January 2010 onwards who 
had not undergone surgical excision for at least one year following confirmed histological 
diagnosis on needle biopsy. Additionally, some women diagnosed between 2003 and 2012 
were identified via the NHSBSP prospective cohort study of screen-detected non-invasive 
neoplasias, the Sloane Project (www.sloaneproject.org.uk).  
 
A comprehensive registration form was completed for each case by the submitting centre, 
including details of the imaging and clinical findings, mode of biopsy, histopathology, 
reasons (where known) for not performing surgery and relevant drug treatment and/or 
radiotherapy. A follow-up form was completed for each subsequent episode, which included 
one or more of clinical assessment, mammogram and ultrasound (continuing drug treatment 
was not formally recorded). A third form was completed for any further needle biopsy or 
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surgery. Forms were returned to the WMCIU / Public Health England where the data were 
entered onto a database. Missing data on tumour characteristics together with date and 
cause of death were obtained from the National Cancer Registration and Analysis Service. 
Data were exported to an Excel spreadsheet for analysis. Registration opened in 2012 and 
closed in December 2016.  
 
2.2. Statistical methods 
Univariate analysis only was performed due to the relatively small size of the dataset. 
Comparisons of categorical data were made using Fisher’s Exact test.  Continuous variables 
were assessed by the Mann-Whitney U test. Cumulative incidence curves were compared 
using Kaplan-Meier analysis and the log rank test. Analysis was conducted using Stata 
version 14 (StataCorp LLC, College Station, Texas, USA). 
 
 
3. RESULTS 
 
3.1. Data from 89 eligible women identified from 31 breast units were returned. In all cases 
the initial DCIS diagnoses were made between 1998 and 2010 (no eligible cases diagnosed 
after 2010 were submitted despite specific requests for such cases). The median patient age 
at diagnosis was 75 years (range 44 - 94 years). The DCIS was screen-detected in 39 
women (44%) with a median age of 65 years; the remaining 50 were diagnosed through 
other routes (symptomatic clinics and incidental findings) and had a median age of 82 years. 
The median duration of follow-up (diagnosis to death, invasive disease or last review) was 
59 months (range 12 - 180 months).  
 
The symptoms of the 50 women who were diagnosed other than through screening are 
poorly documented. Three each presented with a lump, a nipple discharge and nipple 
changes. Clinical examination was recorded as normal in 7, benign in 3, indeterminate in 9, 
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suspicious in 8 and malignant in 8; clinical findings were not recorded in 15. It is likely that a 
number of DCIS lesions were incidentally detected on mammography performed for 
investigation of unrelated symptoms. 
 
Thirty-five women (39%) were recorded as being unfit for surgery (without details of the 
comorbidities), 37 (42%) declined surgery, four (4%) were both unfit and declined surgery, 
other (unspecified) reasons were stated for eight (9%) and the reasons were unknown for 
five (6%) patients. 
 
3.2. Mammographic features 
The predominant mammographic features were known for 75 of the 89 women. Fifty (67%) 
were microcalcification, granular microcalcification being the most common. Nine of the 25 
women with other predominant features (mass or deformity) had microcalcification as a 
secondary feature. The median mammographic lesion size for women in whom both size 
and grade were known was 34 mm (range 8 - 88) for high grade DCIS (n=23), 32 mm (5 - 
126) for intermediate grade DCIS (n=23) and 15 mm (4 - 64) for low grade DCIS (n=11). 
 
3.3. Needle biopsy 
In 63 women, the initial DCIS diagnosis was made with 14-gauge (G) core needle biopsy 
(CNB). Only ten women were known to have been diagnosed with vacuum-assisted biopsy 
(VAB) (one each of 14G and 11G, five 10G and unknown gauge in three). In sixteen women, 
the biopsy technique was classed as either ‘other’ or unknown but were not open biopsies 
(12 were image-guided and one freehand; the remaining three were in women unfit for 
surgery). Of the 72 women where the mode of guidance was known, 37 biopsies were 
performed under stereotaxis, 28 ultrasound and seven freehand. No DCIS diagnoses were 
made solely on fine needle aspiration cytology. 
 
3.4. Cytonuclear grade of DCIS and presence of microinvasion 
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The grade of the DCIS at needle biopsy was known for 77 of the 89 women. Twenty-nine 
were high, 31 intermediate and 17 low grade. Microinvasion was only recorded as definitely 
present in one woman (grade unknown) and possibly present in four (one low grade, one 
intermediate grade, one high grade, one grade not known). Microinvasion was specifically 
stated to be absent on needle biopsy in 59 and not stated (presumed absent) in 25. 
 
3.5 Histological necrosis 
The presence or absence of histological necrosis in association with the DCIS was recorded 
in 53 women. Of the 50 in whom both necrosis status and the primary mammographic 
feature were known, 9/31 with microcalcification and 4/19 with another primary radiological 
feature had necrosis (p= 0.742, Fisher exact test).  
 
3.6. Estrogen receptor (ER) status 
ER status was positive in 43 of the 48 women in whom ER was recorded (positivity was 
regarded as an Allred score ≥3/8 where the score was stated, otherwise as defined by the 
submitting centre). 
 
3.7. Non-surgical treatment 
Forty-four women were treated with endocrine therapy (ET) - 26 with an aromatase inhibitor, 
17 with tamoxifen and one with each type sequentially. One woman treated with an 
aromatase inhibitor also received external beam radiotherapy. Thirty women treated with ET 
were recorded as having known ER positive DCIS. Thirty-five women received no ET; eight 
were known to have ER positive disease. Non-surgical treatment information was not 
available for 10 women. 
 
3.8. Development of invasive cancer 
Twenty-nine women (33%) had invasive breast cancer diagnosed histologically after a 
median interval of 45 months (range 12 - 144 months) following the initial DCIS diagnosis. A 
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further five women who died had invasive breast cancer recorded as their primary cause of 
death on death certification but no histological confirmation of this was recorded on the 
cancer registry; these five were not included amongst those who developed invasive cancer 
for the purposes of this analysis (see discussion). The 29 women who developed proven 
invasive cancer were significantly younger than the 60 who did not (median ages 67 years 
versus 78 years respectively; p=0.0002, Mann-Whitney U-Test). Younger women had a 
similar median length of follow-up to older women (age ≤70 years v. age>70 years: 60 
months v. 58 months; p=0.45; Mann-Whitney U-test), although there was a non-significantly 
higher proportion of younger women with high grade disease (39% v. 27%; p=0.26, Fisher 
exact test). 
 
One invasive cancer was recorded as having developed in the same breast but a different 
quadrant to the known high grade DCIS; this has been included as a case of DCIS 
progression for consistency with other published studies. As far as is known, the remaining 
28 invasive cancers developed at the site of the DCIS. 
 
Comparison of DCIS grade on the initial biopsy and the predominant mammographic feature 
for those with and without progression to invasive cancer is shown in Table 1. After median 
intervals of 38, 60 and 51 months respectively, 14/29 (48%) women with high grade DCIS, 
10/31 (32%) with intermediate grade and 3/17 (18%) with low grade DCIS developed 
invasive cancer; grade was not known in 12. The cumulative incidence of invasive disease 
was significantly higher in women with high grade DCIS than in those with other grades 
(p=0.0016, log-rank test) – Figure 1. None of the five women with microinvasion on the initial 
biopsy developed invasive breast cancer. All six of the grade 3 invasive cancers occurred in 
women with a prior diagnosis of high grade DCIS (Table 2). 
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Twenty-three of the 50 (46%) women with microcalcification as the predominant radiological 
feature developed invasion compared to only five of the 25 (20%) with another known 
predominant radiological feature (p=0.042, Fisher exact test).  
 
Of the 53 women with known histological necrosis status, 7/14 (50%) with necrosis and 
13/39 (33%) without necrosis developed invasive cancer (p=0.341, Fisher exact test). 
 
For those with known DCIS grade and mammographic size, no correlation between lesion 
size and the subsequent development of invasion was demonstrated (p=0.109-0.921; Mann-
Whitney U-test; data not shown). 
 
Nine of 44 women (20%) who received endocrine therapy developed invasive cancer 
compared to 15 of 35 (43%) who did not (p=0.048, Fisher exact test). 
 
Of the 25 known women who did not have microcalcification as the predominant feature, 
four of the 10 (40%) with secondary microcalcification developed invasive cancer compared 
to one of the 15 (7%) without microcalcification (p=0.12, Fisher exact test). 
 
3.9. Surgery 
Eighteen women ultimately underwent breast surgery, seventeen for invasive cancer: 
Thirteen had mastectomy and four wide local excision. One woman had a wide local 
excision for DCIS 12 months after initial diagnosis. 
 
3.10. Deaths 
Forty-eight women died. Eleven of these had biopsy-proven invasive cancer, of whom seven 
had a primary certified cause of death of breast cancer.   
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For women that developed invasive cancer the median interval from diagnosis to death was 
62 months for all-cause deaths and 62 months for deaths from breast cancer. For those that 
did not develop invasive cancer the median interval was 57 months (p=0.28, Mann-Whitney 
U-Test). 
 
Among the 29 women with invasive cancer, there was no significant difference between the 
age at diagnosis of DCIS for those who died compared with the women still alive at census 
(median ages 68 years v. 66 years respectively; p=0.62, Mann-Whitney U-Test). However, 
of the women who did not develop invasive cancer, those who died were significantly older 
at diagnosis than those who remained alive (median ages 83 years v. 69 years; p=0.0001, 
Mann-Whitney U-Test). 
 
 
4. DISCUSSION 
 
This retrospective longitudinal cohort study of women diagnosed with DCIS on core needle 
biopsy who did not undergo surgical excision for at least one year reviewed 89 eligible 
women. Progression to invasive breast cancer was more frequent in a short time frame for 
those with initial DCIS of high cytonuclear grade. The Kaplan-Meier analysis suggests that 
approximately 50% of women with high grade DCIS will develop invasive cancer within five 
years but fewer than 25% of those with lower grade DCIS will develop invasion in the same 
time frame. In particular, low grade DCIS appears to progress slowly to invasive cancer. For 
approximately one in seven of the women who died, the cause of death was attributed to 
breast cancer, with a median survival in these women of over five years from DCIS 
diagnosis. 
 
The tendency for high grade DCIS to be associated with grade 3 invasive cancer and the 
significantly higher cumulative incidence of invasion suggest that the biological behaviour is 
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reflected in the histopathological appearances of the DCIS. This effect of grade is similar to 
that seen for DCIS recurrence following surgical resection. [15] Our findings emphasise the 
importance of early detection and treatment of women with high grade DCIS in order to 
prevent the development of high grade invasive cancer. 
 
Even with the confounding factor of a slightly higher proportion of high grade disease in the 
younger (≤70 years) women, the rate of progression to invasion does appear to be higher in 
younger women. This is in keeping with the known higher local recurrence rate in younger 
women following surgical resection of DCIS [1,16,17] and with the higher proportion of 
invasive recurrences seen in these women. [18] 
 
 
The apparent association of DCIS microcalcification with the development of invasive 
disease has not been previously reported, although microcalcification has been shown to be 
associated with a higher risk of non-invasive recurrence. [19] In addition, there have been 
some suggestions that invasive cancers with microcalcification have a worse prognosis than 
non-calcified lesions, [20,21,22] although this is not a consistent finding [23] and may be due 
to confounding factors. [24] Our findings are rather at variance with those of other studies 
which have shown a higher upstaging rate at surgery of DCIS with an associated 
mammographic mass, [25,26] and the small number of women with masses in this study 
precludes further analysis of possible confounding factors. 
 
The effect of endocrine therapy in reducing progression of DCIS to invasive cancer noted 
here is consistent with the findings of trials of adjuvant endocrine therapy following surgery 
for DCIS. The UK/ANZ DCIS trial [27] and the NSABP B-24 study [28] demonstrated a 
significant reduction in the frequency of DCIS recurrence with tamoxifen, although the 
UK/ANZ study did not show a significant reduction in invasive recurrence. Anastrozole has 
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subsequently been demonstrated to be at least as effective as tamoxifen in this setting. 
[29,30] 
 
The contribution of DCIS detection at screening to reduction of breast cancer mortality has 
long been debated. A review of prior mammograms of women with incident screen-detected 
cancers suggested that undiagnosed calcified DCIS progresses to invasive cancer within the 
three-year period between screens in a significant number of women, [31] but only recently 
have data been published that demonstrate that high DCIS detection rates at screening are 
associated with a reduction in the incidence of interval cancers. [32] 
 
Sagara et al [4] reported outcomes of 57,222 women with DCIS from the SEER 
(Surveillance, Epidemiology and End Results) database, of whom 1169 (2%) had not 
undergone surgical resection. Although the development of invasive disease was not 
specifically examined, for women with high and intermediate grade DCIS there was a 
significant difference in 10-year breast cancer specific survival between those who 
underwent surgery and those who did not (98.4% v. 90.5%, p<0.001, for high grade; 98.6% 
v. 94.6%, p<0.001, for intermediate grade disease, respectively). Surgery was not, however, 
associated with a survival difference in women with low grade DCIS (98.6% v. 98.8%; 
P=0.95). The median follow-up, however, was only six years, and further study is required to 
determine whether this effect persists in the longer term (cf. the discussion below about long 
term recurrence rates after surgery). A series following 14 women with ER positive DCIS 
who underwent endocrine therapy as an alternative to immediate surgery [6] reported that 
eight subsequently had surgery after a median follow-up of 28 months; five had with stage I 
invasive ductal cancers. Although there were only 17 women with low grade DCIS in the 
present study, eight died of non-breast cancer related causes and the findings suggest that 
low grade DCIS is a relatively indolent disease. Of the three women who did develop 
invasion after intervals of 46, 51 and 137 months, one of the invasive cancers was of 
histological grade 1, one grade 2 and the other was of unknown grade. These findings, 
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together with the demonstrated lack of survival benefit from surgery, [4] also support 
ongoing studies of active surveillance as an alternative to surgery in low risk DCIS. [8,9,10] 
 
To our knowledge, this is the largest study reporting the progression of histologically 
confirmed unresected DCIS to invasive breast cancer. Diagnostic and treatment data were 
obtained from clinicians managing the women, supplemented by cancer registry data, and 
consequently data completeness is relatively high. Although variability in the application of 
diagnostic and grading criteria to DCIS by histopathologists is well recognised, [33] the 
mandatory participation in a national quality assurance programme by all UK pathologists 
working in breast screening [34] provides some reassurance. 
 
This study has limitations. Despite the large number of women with a DCIS diagnosis but no 
record of surgery on the cancer registries (2505 (5%) potentially eligible out of a total of 
49,567 DCIS registrations in the period 1996-2009), only a relatively small number of 
patients (0.2%) had data submitted by the treating centres, with potential for selection bias. 
The proportion of women diagnosed with DCIS in the UK who do not undergo surgery is, 
therefore, unknown, but appears similar to the 2.0 - 2.3% reported in the USA. [4,13] 
Because of the nature of the study population (with regard to patient age and associated co-
morbidities), many of the women died of competing causes during the course of the study, 
substantially limiting the duration of follow-up. Furthermore, there were relatively few 
younger women with screen-detected DCIS. Given that DCIS is most commonly diagnosed 
through screening, [35,36] the disproportionate number of women in this study with DCIS 
diagnosed through other routes (either symptomatic or incidentally detected on 
mammography performed for investigation of unrelated symptoms) is probably because 
screening mammography in the UK is targeted at women aged 70 years of age or younger 
who are more likely to be suitable for, and to be willing to undergo, primary surgical 
resection of DCIS than older women who were diagnosed outside the screening service. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16 
Although endocrine treatment was recorded on the initial assessment form it was not 
recorded on the subsequent forms and it is possible that some women stopped treatment, or 
conversely that others commenced treatment. 
 
Five women died with a primary certified cause of death of breast cancer but no 
corresponding cancer registration of invasive breast cancer. These have not been included 
as having developed invasive disease in the analysis. This is because there is known to be a 
high discrepancy rate in death certification, with up to a third of deaths being incorrectly 
certified, [37] whereas the UK cancer registries (now unified as the National Cancer 
Registration and Analysis Service) have an ascertainment rate of around 98%. [38] It is, 
however, possible that the number of women who developed invasive cancer has been 
slightly understated. 
 
Although the rate of development of invasive cancer in women with low grade DCIS appears 
to be much lower than that in women with high grade DCIS in the short term (the median 
follow-up was just under 5 years), it is not possible to determine the longer-term behaviour of 
low grade DCIS from this study. Solin et al, [39] in a study of 268 women with DCIS treated 
by wide local excision and radiotherapy, demonstrated that the local recurrence rate of high 
grade DCIS with necrosis was four times that of the other lesions at 5 years (12% v 3%) but 
that continued recurrences in the less aggressive group brought the rates much closer 
together by 10 years (18% v. 15%). A similar but less marked effect was seen in the Early 
Breast Cancer Trialists' Collaborative Group overview of randomised radiotherapy trials in 
DCIS. [40] The proportion of women developing invasive cancer can, therefore, be expected 
to be higher in a population with a longer life expectancy, especially as the rate of 
progression appears to be higher in younger women.  
 
The majority of women in the study underwent conventional core needle biopsy rather than 
vacuum-assisted biopsy for diagnosis. CNB is known to underestimate the coexistence of 
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invasive disease in DCIS in approximately 20% of cases. [25,41,42] Nonetheless, the study 
still allows a ‘real world’ approach to the outcome of DCIS diagnosed predominantly at CNB 
to be determined. Finally, due to the relatively small number of subjects, multivariable 
analysis was not possible, thus confounding factors cannot be excluded.  
 
 
5. CONCLUSIONS 
 
High cytonuclear grade of DCIS, mammographic microcalcification, young age and lack of 
endocrine therapy were significant risk factors for progression to invasive breast cancer after 
a median interval of 45 months in this group of women diagnosed with DCIS on needle 
biopsy but who did not undergo surgical resection for at least one year. These findings 
suggest that complete surgical excision of high grade DCIS should continue, as per current 
standard of care protocols. The natural history of low grade DCIS, however, remains 
uncertain. Whilst there are concerns about possible overtreatment of women with this 
condition, established management practice should not be changed in the absence of firm 
evidence, and the option of active surveillance for women with non-high grade DCIS should 
be offered within the context of a clinical trial.  
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 18 
ETHICAL APPROVAL 
 
This study did not require ethical approval, as it is an audit using data obtained as part of 
usual patient care. UK cancer registries have approval under Section 251 of the UK National 
Health Service Act 2006 to collect all diagnostic and treatment information for cancer 
patients without the patient's implicit consent. 
 
ACKNOWLEDGEMENTS 
 
The authors would like to thank all the clinicians who submitted patient data. 
Dr Elaine Harness, Division of Informatics Imaging & Data Sciences, School of Health 
Sciences, Faculty of Biology Medicine and Health, University of Manchester, UK provided 
valuable assistance with the statistical analysis. 
The contributions of Mr Hugh M Bishop, former Steering Group Chair, and of Professor 
Adele Francis (now deceased) to this study are acknowledged. 
This study has been accepted for poster presentation at the San Antonio Breast Cancer 
Symosium, December 2017. 
The authors declare no conflicts of interest. 
 
FUNDING 
 
The study received no specific funding. The data were collated, maintained and quality 
assured by the Screening Quality Assurance Service and the National Cancer Registration 
and Analysis Service, which are part of Public Health England, a publicly funded executive 
agency of the UK Department of Health, established in 2013.  Prior to this, the data were 
collected, maintained and quality assured by the publicly funded West Midlands Cancer 
Intelligence Unit. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 19 
DD is supported by the University of Oxford, Cancer Research UK (grant C8225/A21133), 
the Medical Research Council and the British Heart Foundation. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20 
APPENDIX 
 
Members of the Sloane Project Steering Group at the time of writing: 
 
Professor Alastair Thompson (Chair of the Sloane Project Steering Group)    
Professor of Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas, 
USA 
 
Mrs Karen Clements                 
National Audit Project Senior QA Officer, Screening QA Service (Midlands and East), Public 
Health England, Birmingham, UK 
 
Dr Hilary Dobson              
Consultant Radiologist, West of Scotland Breast Screening Programme, Glasgow, UK 
Professor David Dodwell          
Professor of Clinical Oncology, St James's Institute of Oncology, Leeds, UK 
 
Professor Andrew Evans                 
Professor of Breast Imaging, Ninewells Hospital and Medical School, Dundee, UK 
 
Professor Andrew Hanby 
Professor of Breast Cancer Pathology, St James's University Hospital, Leeds, UK 
 
Mrs Bridget Hilton                 
National Audit Project Senior QA Officer, Screening QA Service (Midlands and East), Public 
Health England, Birmingham, UK 
 
Mrs Olive Kearins                     
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 21 
Head of QA, Screening QA Service (Midlands and East), Public Health England, 
Birmingham, UK 
 
Dr Gill Lawrence 
Specialist Audit Advisor, UK 
 
Dr Anthony Maxwell         
Consultant Radiologist, Nightingale Centre, University Hospital of South Manchester, 
Manchester, UK 
 
Professor Sarah Pinder            
Professor of Breast Pathology, Guys and St Thomas’ Hospitals, London 
 
Dr Elinor Sawyer 
BRC Clinical Research Consultant in Clinical Oncology, Guys Hospital, London, UK 
 
Mr Mark Sibbering           
Consultant Surgeon, Derby City General Hospital, Derby, UK 
 
Professor Valerie Speirs              
Professor of Experimental Pathology and Oncology, Leeds Institute of Cancer and 
Pathology, University of Leeds, Leeds, UK 
 
Dr Jeremy Thomas              
Consultant Pathologist, Western General Hospital, Edinburgh, UK 
 
Professor Ian Tomlinson          
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 22 
Professor of Molecular and Population Genetics, Wellcome Trust Centre for Human 
Genetics, Oxford, UK 
 
Professor Graham Ball      
Reader in Bioinformatics, Nottingham Trent University, Nottingham, UK 
 
Dr Matthew Wallis            
Consultant Radiologist, Addenbrooke’s Hospital, Cambridge, UK 
 
Ms Maggie Wilcox 
Patient Advocate, Independent Cancer Patients' Voice, UK 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 23 
REFERENCES 
 
1. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a 
systematic review of incidence, treatment, and outcomes. JNCI Journal of the 
National Cancer Institute 2010;102(3):170–8. 
2. Independent UK Panel on Breast Cancer Screening. The benefits and harms of 
breast cancer screening: an independent review. The Lancet 2012;380(9855):1778–
86. 
3. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a 
diagnosis of ductal carcinoma in situ. JAMA Oncol 2015;1(7):888–96. 
4. Sagara Y, Mallory MA, Wong S, et al. Survival benefit of breast surgery for low-grade 
ductal carcinoma in situ. JAMA Surg 2015;150(8):739–45. 
5. Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing 
better than something? Lancet Oncol 2016;17(10):e442–51. 
6. Meyerson AF, Lessing JN, Itakura K, et al. Outcome of long term active surveillance 
for estrogen receptor-positive ductal carcinoma in situ. Breast 2011;20(6):529–33. 
7. Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES. Outcomes of active 
surveillance for ductal carcinoma in situ: a computational risk analysis. JNCI Journal 
of the National Cancer Institute 2016;108(5):djv372. 
8. Francis A, Thomas J, Fallowfield L, et al. Addressing overtreatment of screen 
detected DCIS; the LORIS trial. Eur J Cancer 2015;51(16):2296–303. 
9. Patient-Centered Outcomes Research Institute. Comparison of Operative versus 
Medical Endocrine Therapy for Low Risk DCIS: The COMET Trial. 
http://www.pcori.org/research-results/2016/comparison-operative-versus-medical-
endocrine-therapy-low-risk-dcis-comet (accessed 18 May 2017). 
10. Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-
label, international multicentre, phase III, non-inferiority trial to assess the safety of 
active surveillance for low risk ductal carcinoma in situ – The LORD study. Eur J 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24 
Cancer 2015;51(12):1497–510. 
11. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in 
situ of the breast: a review. Breast Cancer Res Treat 2006;97(2):135–44. 
12. Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for 
ductal carcinoma in situ of the breast: how much more breast cancer can we find? 
Ann Intern Med 1997;127(11):1023–8. 
13. Worni M, Greenup RA, Mackey AM, Akushevich I. Trends in treatment patterns and 
outcomes for DCIS patients: A SEER population-based analysis. J Clin Oncol 
2014;32(15_suppl):1007. 
14. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing 
the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 2011;129(1):165–
73. 
15. Wallis MG, Clements K, Kearins O, Ball G, Macartney J, Lawrence GM. The effect of 
DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-
detected DCIS. Br J Cancer 2012;106(10):1611–7. 
16. Vicini FA, Shaitelman S, Wilkinson JB, et al. Long-term impact of young age at 
diagnosis on treatment outcome and patterns of failure in patients with ductal 
carcinoma in situ treated with breast-conserving therapy. Breast J 2013;19(4):365–73.  
17. Kong I, Narod SA, Taylor C, et al. Age at diagnosis predicts local recurrence in 
women treated with breast-conserving surgery and postoperative radiation therapy for 
ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol 
2014;21(1):e96–e104. 
18. Cronin PA, Olcese C, Patil S, Morrow M, Van Zee KJ. Impact of age on risk of 
recurrence of ductal carcinomain situ: outcomes of 2996 women treated with breast-
conserving surgery over 30 years. Ann Surg Oncol 2016;23(9):2816–24. 
19. Holmberg L, Wong YNS, Tabár L, et al. Mammography casting-type calcification and 
risk of local recurrence in DCIS: analyses from a randomised study. Br J Cancer 
2013;108(4):812–9. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 25 
20. Thurfjell E, Thurfjell MG, Lindgren A. Mammographic finding as predictor of survival in 
1-9 mm invasive breast cancers. Worse prognosis for cases presenting as 
calcifications alone. Breast Cancer Res Treat 2001;67(2):177–80. 
21. Tabar L, Chen H-HT, Yen MFA, et al. Mammographic tumor features can predict long-
term outcomes reliably in women with 1–14-mm invasive breast carcinoma. Cancer 
2004;101(8):1745–59. 
22. Peacock C, Given-Wilson RM, Duffy SW. Mammographic casting-type calcification 
associated with small screen-detected invasive breast cancers: is this a reliable 
prognostic indicator? Clin Radiol 2004;59(2):165–70. 
23. James JJ, Evans AJ, Pinder SE, Macmillan RD, Wilson ARM, Ellis IO. Is the presence 
of mammographic comedo calcification really a prognostic factor for small screen-
detected invasive breast cancers? Clin Radiol 2003;58(1):54–62. 
24. Evans AJ, James JJ, Pinder SE. Mammographic casting-type calcification associated 
with small screen-detected invasive breast cancers: is this a reliable prognostic 
indicator? Clin Radiol 2004;59(2):163–4. 
25. Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle 
biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. 
Radiology 2011;260(1):119–28. 
26. Jakub JW, Murphy BL, Gonzalez AB, et al. A validated nomogram to predict 
upstaging of ductal carcinoma in situ to invasive disease. Ann Surg Oncol 
2017;24(10):2915–24. 
27. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women 
with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS 
trial. Lancet Oncol 2011;12(1):21–9.  
28. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast 
cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised 
controlled trial. The Lancet 1999;353(9169):1993–2000. 
29. Forbes JF, Sestak I, Howell A, et al. Anastrozole versus tamoxifen for the prevention 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 26 
of locoregional and contralateral breast cancer in postmenopausal women with locally 
excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled 
trial. The Lancet 2016;387(10021):866–73. 
30. Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in 
postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus 
radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The 
Lancet 2016;387(10021):849–56. 
31. Maxwell AJ, Hanson IM, Sutton CJ, Fitzgerald J, Pearson JM. A study of breast 
cancers detected in the incident round of the UK NHS Breast Screening Programme: 
the importance of early detection and treatment of ductal carcinoma in situ. Breast 
2001;10(5):392–8. 
32. Duffy SW, Dibden A, Michalopoulos D, et al. Screen detection of ductal carcinoma in 
situ and subsequent incidence of invasive interval breast cancers: a retrospective 
population-based study. Lancet Oncol 2016;17(1):109–14. 
33. Elston CW, Sloane JP, Amendoeira I, et al. Causes of inconsistency in diagnosing 
and classifying intraductal proliferations of the breast. Eur J Cancer 
2000;36(14):1769–72. 
34. Ellis IO, Coleman DA, Wells C, et al. Impact of a national external quality assessment 
scheme for breast pathology in the UK. J Clin Pathol 2006;59(2):138–45. 
35. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence of and 
treatment for ductal carcinoma in situ of the breast. JAMA 1996;275(12):913–8. 
36. Barnes NLP, Dimopoulos N, Williams KE, Howe M, Bundred NJ. Eur J Surg Oncol 
2014;40(3):249–54. 
37. Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical and autopsy 
diagnosis and the value of post mortem histology; a meta-analysis and review. 
Histopathology 2005;47(6):551–9. 
38. Møller H, Richards S, Hanchett N, et al. Completeness of case ascertainment and 
survival time error in English cancer registries: impact on 1-year survival estimates. Br 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 27 
J Cancer 2011;105(1):170–6. 
39. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery 
and definitive breast irradiation for the treatment of ductal carcinoma in situ of the 
breast. J Clin Oncol 1996;14(3):754–63. 
40. Early Breast Cancer Trialists' Collaborative Group EBCTCG. Overview of the 
randomized trials of radiotherapy in ductal carcinoma In situ of the breast. J Natl 
Cancer Inst Monogr 2010;2010(41):162–77. 
41. Doebar SC, de Monyé C, Stoop H, Rothbarth J, Willemsen SP, van Deurzen CHM. 
Ductal carcinoma in situ diagnosed by breast needle biopsy: predictors of invasion in 
the excision specimen. Breast 2016;27:15–21. 
42. Caswell-Smith P, Wall M. Ductal carcinoma in situ: is core needle biopsy ever 
enough? J Med Imaging Radiat Oncol 2017;61(1):29–33. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
TABLE 1 
 
Predominant radiological feature and cytonuclear grade of DCIS at core needle 
biopsy (denominators) and numbers that developed invasive cancer (numerators). 
 
Predominant 
radiological feature 
Low grade Intermediate 
grade 
High grade Grade not 
known 
Total 
Microcalcification - 
casting 
0/1 3/8 3/6 1/2 7/17  
 
 
 
 
micro- 
calcific- 
ation 
 
23/50 
Microcalcification - 
granular 
1/2 4/9 5/8 0/0 10/19 
Microcalcification - 
punctate 
2/3 0/0 1/2 0/0 3/5 
Microcalcification - 
pattern not known 
0/0 1/6 2/2 0/1 3/9 
Mass – ill-defined 0/1 1/1 0/1 1/1 2/4  
 
 
 
mass 
 
5/18 
Mass – well-defined 0/2 0/1 2/4 0/3 2/10 
Spiculate mass 0/2 0/0 1/1 0/1 1/4 
Stromal deformity 0/0 0/0 0/2 0/0 0/2  
None of the above 0/3 0/1 0/0 0/1 0/5 
Not known 0/3 1/5 0/3 0/3 1/14 
Total 3/17 10/31 14/29 2/12 29/89 
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TABLE 2 
 
Invasive carcinoma type and histological grade and the cytonuclear grade of the 
original DCIS, where known.  
 
Original DCIS 
grade 
IDC grade 1 IDC grade 2 IDC grade 3 Other invasive 
cancer 
Not 
known 
Total 
High 0 2 6 1 invasive lobular 
carcinoma grade 2 
5 14 
Intermediate 2 3 0 1 mixed carcinoma 4 10 
Low 
 
1 1 0 0 1 3 
Not known 0 0 0 1 invasive lobular 
carcinoma grade 2; 
1 invasive papillary 
carcinoma 
0 2 
Total 
 
3 6 6 4 10 29 
 
IDC – Invasive ductal carcinoma 
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